Trevi Therapeutics (TRVI) Accounts Payables (2018 - 2026)

Trevi Therapeutics has reported Accounts Payables for 9 years, with the latest figure at $2.2 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables rose 55.88% year-over-year to $2.2 million; the trailing twelve-month figure through Mar 2026 stood at $2.2 million (up 55.88% YoY), and the FY2025 full-year result was $3.9 million, up 14.56% from the prior year.
• Accounts Payables for Q1 2026 stood at $2.2 million, down from $3.9 million in the prior quarter.
• The five-year high for Accounts Payables was $3.9 million in Q2 2022, with the low at $1.3 million in Q3 2023.
• Average Accounts Payables over 5 years is $2.3 million, with a median of $2.1 million recorded in 2024.
• Year-over-year, Accounts Payables jumped 116.98% in 2022 and plunged 65.67% in 2023.
• Tracing TRVI's Accounts Payables over 5 years: stood at $2.9 million in 2022, then sank by 36.68% to $1.8 million in 2023, then surged by 88.72% to $3.4 million in 2024, then climbed by 14.56% to $3.9 million in 2025, then tumbled by 43.36% to $2.2 million in 2026.
• The last three Accounts Payables figures came in at $2.2 million (Q1 2026), $3.9 million (Q4 2025), and $2.7 million (Q3 2025), per Business Quant data.

Peer Comparison